Kura Oncology Stock News

Kura Oncology (NASDAQ:KURA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, �

Stocks Analysis by Harry Boxer covering: MGM Resorts International, Fluor Corporation, Builders FirstSource Inc, Avadel Pharmaceuticals PLC. Read Harry Boxer's latest article on Investing.com

Shares of Kura Oncology (NASDAQ: KURA) -- a clinical-stage biopharmaceutical company that focuses on developing cancer treatments -- were up by 42.6% as of 1:49 p.m. EDT on Tuesday. The company did n

Gainers Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) shares jumped 68.6% to $19.40 after the company presented positive preclinical and initial clinical data for SNDX-5613, its...

Kura Oncology (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday, Zacks.com reports. The firm currently has a $12.00

Roche Holdings AG Basel (OTCMKTS:RHHBY) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of th

Kura Oncology Inc:

Kura Oncology (NASDAQ:KURA) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a report issued on Wednesday, BidAskClub reports. Several other equities research analysts als

Bank of America Corp DE decreased its stake in Kura Oncology Inc (NASDAQ:KURA) by 15.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Comm

The U.S. restaurant chain that is majority owned by a Japanese company said on Wednesday it would be returning the emergency government funding it received.

Bank of New York Mellon Corp grew its position in shares of Kura Oncology Inc (NASDAQ:KURA) by 2.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Com

Exane Derivatives purchased a new position in Kura Oncology Inc (NASDAQ:KURA) during the 1st quarter, HoldingsChannel reports. The firm purchased 9,705 shares of the company’s stock, valued at appro

Bailard Inc. raised its stake in Kura Oncology Inc (NASDAQ:KURA) by 14.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 48,434 sha

Kura Oncology (NASDAQ:KURA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks.com reports

Kura Oncology (NASDAQ:KURA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, Zacks.com reports. The brokerag